NASDAQ: AGMB · Life Sciences · 7 alerts · CIK 2020932
Share price
$5.97Close, Nov 16
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All AgomAb Therapeutics NV filings on SEC EDGAR ↗
AgomAb Therapeutics Insider David R. Epstein Buys $88.6K of Stock
David R. Epstein bought 14,960 shares of AgomAb Therapeutics NV at $5.75 to $6.02 a share (average $5.92) in 3 transactions, worth $88.6K in total on Nov 13, 2026. Shares held after the trade: 54,980 (+9.9%).
AgomAb Therapeutics Insider David R. Epstein Buys $104K of Stock
David R. Epstein bought 15,000 shares of AgomAb Therapeutics NV at $6.81 to $6.98 a share (average $6.90) in 3 transactions, worth $104K in total on Nov 5, 2026. Shares held after the trade: 40,000 (+14.3%).
AgomAb Therapeutics Insider David R. Epstein Buys $88.8K of Stock
David R. Epstein bought 10,000 shares of AgomAb Therapeutics NV at $8.86 to $8.90 a share (average $8.88) in 2 transactions, worth $88.8K in total on Oct 21, 2026. Shares held after the trade: 25,000 (+25.0%).
AgomAb Therapeutics Insider David R. Epstein Buys $44.5K of Stock
David R. Epstein bought 5,000 shares of AgomAb Therapeutics NV at $8.90 a share, worth $44.5K in total on Oct 8, 2026. Shares held after the trade: 15,000 (+50.0%).
AgomAb Therapeutics Insider David R. Epstein Buys $86.3K of Stock
David R. Epstein bought 10,000 shares of AgomAb Therapeutics NV at $8.57 to $8.70 a share (average $8.63) in 2 transactions, worth $86.3K in total between Oct 5, 2026 and Oct 6, 2026. Shares held after the trade: 10,000 (+100.0%).
AgomAb Therapeutics CFO Pierre Thadee Victor Kemula Buys $85.9K of Stock
Pierre Thadee Victor Kemula, CFO, bought 10,000 shares of AgomAb Therapeutics NV at $8.54 to $8.67 a share (average $8.59) in 3 transactions, worth $85.9K in total on Oct 6, 2026. Shares held after the trade: 10,000 (+25.0%).
AgomAb Therapeutics CEO Tim Jasper Knotnerus Buys $94.4K of Stock
Tim Jasper Knotnerus, CEO, bought 11,000 shares of AgomAb Therapeutics NV at $8.48 to $8.70 a share (average $8.58) in 2 transactions, worth $94.4K in total between Oct 5, 2026 and Oct 6, 2026. Shares held after the trade: 21,823 (+29.7%).